158661-55-3

Upstream product

• 6965-19-1 2-ethylthio-3H-pyrimidin-4-one 
• 62-53-3 aniline 
• 5751-20-2 2-Methylthiouracil 
• 110235-28-4 (4-methoxy-pyrimidin-2-yl)-phenyl-amine 
• 5751-20-2 2-methylthio-1H-pyrimidin-4-one 
• 5751-20-2 2-(methylsulfanyl)pyrimidin-4-ol 

Downstream Products

• 946505-60-8 5-bromo-2-(phenylamino)pyrimidin-4(3H)-one 
• 52057-92-8 4-chloro-N-phenylpyrimidin-2-amine 
• 1033942-68-5 1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-2-phenylamino-1H-pyrimidin-4-one 
• 1033942-74-3 1-(2-deoxy-3,5-di-O,O-(4-methylbenzoyl)-β-D-ribofuranosyl)-2-phenylamino-1H-pyrimidin-4-5one 
• 1033942-77-6 1-(2-deoxy-3,5-di-O,O-(4-methylbenzoyl)-α-D-ribofuranosyl)-2-phenylamino-1H-pyrimidin-4-one 
• 950752-51-9 4-(4-chloro-pyrimidin-2-ylamino)-N-cyclohexyl-benzenesulfonamide 
• 919836-53-6 4-(4-chloro-pyrimidin-2-ylamino)-benzenesulfonyl chloride 

Relevant academic research and scientific papers

PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS

The invention provides novel pyridinamine-pyridone and pyrimidinamine- pyridone compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, type II diabetes, inflammatory disease, neurodegenerative disorders, cardiovascular disorders, autoimmune diseases and viral infections; (I) wherein R1, R2, R3 and Z are as defined in the specification.

NOVEL PHENYL(4-PHENYLPYRIMIDIN-2-YL)AMINE DERIVATIVES, THEIR PREPARATION, AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS

The disclosure relates to a compound of formula (I): wherein R, R2, R3, R4, R5, Z, W and D are as defined in the specification, to compositions containing them, to processes for preparing them, and to their use in the treatment or prevention of conditions

2-ANILINO-4-HETEROARYL PYRIMIDINE DERIVATIVES, AND PREPARATION THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS, AND IN PARTICULAR IKK INHIBITORS

The disclosure relates to a compound of formula (I): wherein R, R2, R3, R4, R5, z, D and W are as defined in the specification, to compositions containing them, to processes for preparing them, and to their use in the treatment or prevention of conditions capable of being modulated by the inhibition of the activity of protein kinases.

Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors

The disclosure relates to compounds of formula (I): wherein R1-R5, A and Y are as defined in the disclosure, to compositions comprising said compounds, and to processes for making and methods of using the same.

Synthesis of N 2-Arylisocytidines and N 2-Aryl- 2′-deoxyisocytidines

2-(Arylamino)pyrimidin-4-ones were synthesized, silylated, and condensed with l,2,3,5-tetra-O-acetyl-β- d-ribofuranoside to afford the corresponding N 2-aryl protected isocytidines. Deprotection of the acetylated isocytidines using saturated NH

QUINOLINE COMPOUNDS AND METHODS OF USE

Compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof, are useful for inhibiting receptor tyrosine kinases and for treating hyperproliferative disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. [ Formula I]

Heterobicyclic thiophene compounds and methods of use

Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Heterobicyclic pyrazole compounds and methods of use

Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

2,4-DIAMINO PYRIMIDINE COMPOUNDS HAVING ANTI-CELL PROLIFERATIVE ACTIVITY

A pyrimidine derivative of formula (I) wherein, for example, R1 is hydrogen, (1-6C)alkyl, (3-5C)alkenyl or (3-5C)alkynyl; Q1 and Q2 are independently selected from phenyl, naphthyl, indanyl and 1,2,3,4-tetrahydronaphthyl; and one or both of Q1 and Q2 bear

A facile preparation of n2-arylisocytosines

N2-Arylisocytosines were obtained in good yields varying from 59 to 96% by a simple two-step process starting from 2-thiouracil via readily accessible 2-(methylthio)pyrimidin-4(3H)-one.